Literature DB >> 28559028

Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.

Cheng Xu1, Yu-Pei Chen1, Xu Liu1, Wen-Fei Li1, Lei Chen1, Yan-Ping Mao1, Yuan Zhang1, Rui Guo1, Guan-Qun Zhou1, Ling-Long Tang1, Ai-Hua Lin2, Ying Sun1, Jun Ma3.   

Abstract

OBJECTIVES: The subgroups of patients with nasopharyngeal carcinoma (NPC) who benefit from induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) remain unclear.
MATERIALS AND METHODS: We established prognostic nomograms for overall survival (OS) and disease-free survival (DFS), and validated the nomograms in 1230 patients with NPC and subgroup of 923 patients with locoregionally advanced NPC (LANPC). Three well-matched risk groups (i.e., low, intermediate and high risk) were created via recursive partitioning and 1-to-1 propensity score matching; IC+CCRT was compared with CCRT in each risk group.
RESULTS: Histological type, T category, N category, plasma Epstein-Barr virus deoxyribonucleic acid (and the same factors plus age and neutrophil-lymphocyte ratio) were included in the nomograms for DFS (and OS). Both nomograms had higher c-indexes than the 7th edition staging system in both NPC/LANPC (all P-values≤0.010). The nomogram for OS also had a higher c-index in LANPC than the 8th edition staging system (P-value=0.052). OS was significantly different between all three risk groups in the individualized risk stratification (all P-values<0.001), while the 7th and 8th edition staging systems failed to clearly separate OS for stage II and III disease (P-value=0.415 and 0.347, respectively). IC+CCRT improved OS in intermediate and high risk patients with LANPC compared to CCRT alone (P-value<0.001 and P-value=0.002, respectively).
CONCLUSION: These prognostic nomograms could accurately guide treatment of individual patients with NPC. IC+CCRT could improve OS for patients with LANPC at intermediate to high risk.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Concurrent chemoradiotherapy; Induction chemotherapy; Nasopharyngeal carcinoma; Nomograms; Survival; TNM staging system

Mesh:

Year:  2017        PMID: 28559028     DOI: 10.1016/j.oraloncology.2017.04.015

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  18 in total

1.  Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases.

Authors:  Qi-Yong Ai; Chen-Wen Hu; Kunwar S Bhatia; Darren M C Poon; Edwin P Hui; Frankie K F Mo; Benjamin King Hong Law; Macy Tong; Brigette B Ma; Anthony T C Chan; Ann D King
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-29       Impact factor: 2.503

2.  A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma.

Authors:  Pu-Yun OuYang; Xiao-Min Zhang; Xing-Sheng Qiu; Zhi-Qiao Liu; Lixia Lu; Yuan-Hong Gao; Fang-Yun Xie
Journal:  Oncologist       Date:  2019-02-19

3.  Prognostic significance of MRI-based late-course tumor volume in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Ge Yan; Yan Feng; Mingyao Wu; Chao Li; Yiran Wei; Li Hua; Guoqi Zhao; Zhekai Hu; Shengyu Yao; Lingtong Hou; Xuming Chen; Qianqian Liu; Qian Huang
Journal:  Radiat Oncol       Date:  2022-06-27       Impact factor: 4.309

4.  Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.

Authors:  Xing-Li Yang; Yan Wang; Shao-Bo Liang; Sha-Sha He; Dan-Ming Chen; Hai-Yang Chen; Li-Xia Lu; Yong Chen
Journal:  BMC Cancer       Date:  2018-05-29       Impact factor: 4.430

5.  Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.

Authors:  Cheng Xu; Shi-Ping Yang; Yuan Zhang; Ling-Long Tang; Guan-Qun Zhou; Xu Liu; Yan-Ping Mao; Rui Guo; Wen-Fei Li; Lei Chen; Ai-Hua Lin; Ying Sun; Jun Ma
Journal:  Cancer Res Treat       Date:  2017-07-24       Impact factor: 4.679

6.  Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data.

Authors:  Cheng Xu; Shu Zhang; Wen-Fei Li; Lei Chen; Yan-Ping Mao; Ying Guo; Qing Liu; Jun Ma; Ling-Long Tang
Journal:  Front Oncol       Date:  2019-11-29       Impact factor: 6.244

7.  The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma.

Authors:  Zhong-Guo Liang; Fan Zhang; Bin-Bin Yu; Ling Li; Song Qu; Ye Li; Ying Guan; Ren-Ba Liang; Lu Han; Xiao-Dong Zhu
Journal:  Cancer Manag Res       Date:  2020-02-04       Impact factor: 3.989

8.  Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era.

Authors:  Zhen Su; Guo-Rong Zou; Jie Tang; Xiu Yue Li; Fang-Yun Xie
Journal:  Ther Clin Risk Manag       Date:  2020-03-26       Impact factor: 2.423

9.  Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Yanming Jiang; Song Qu; Xinbin Pan; Shiting Huang; Xiaodong Zhu
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

10.  Staging of T2 and T3 nasopharyngeal carcinoma: Proposed modifications for improving the current AJCC staging system.

Authors:  Chunyan Cui; Haojiang Li; Huali Ma; Annan Dong; Fei Xie; Shaobo Liang; Li Li; Jian Zhou; Chuanbo Xie; Yue Yan; Lizhi Liu
Journal:  Cancer Med       Date:  2020-09-01       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.